Welcome to our dedicated page for EXOZYMES SEC filings (Ticker: EXOZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
eXoZymes Inc. SEC filings document a Nevada biotechnology issuer with common stock listed on the Nasdaq Capital Market under the symbol EXOZ. The filing record is centered on Form 8-K Item 8.01 current reports that furnish investor presentations, press releases, and exhibit materials.
These filings disclose company communications about the exozyme cell-free biomanufacturing platform, NCTx business materials, NCT production scale-up, commercial-readiness updates, and capital-markets presentation materials associated with securities offering activity. They also identify the registered common stock class, exchange listing, exhibit filings, and formal signatures required under Exchange Act reporting.
EXOZYMES INC. (EXOZ) reported that Chief Executive Officer Michael Heltzen increased his direct holdings of common stock through several transactions in August 2026. On August 25–26, 2026, he purchased a total of 855 shares in open market or private transactions at prices between $7.35 and $7.60 per share. On August 19, 2026, he also acquired 8,841 shares as a grant or award at $6.40 per share. No Rule 10b5-1 trading plan is reported for these transactions.
EXOZYMES INC. (EXOZ) reported that Chief Commercial Officer Damien Alan Perriman exercised restricted stock units into common shares. On August 19, 2026, he converted 19,612 RSUs into 19,612 shares of common stock from a January 14, 2026 grant of 62,759 RSUs. Following these transactions, he directly holds 28,499 common shares and 43,147 RSUs that continue to vest periodically.
EXOZYMES INC. (EXOZ) reported that Chief Scientific Officer Korman Tyler Paz exercised 32,964 Restricted Stock Units into 32,964 shares of Common Stock on August 19, 2026. The RSUs convert on a one-for-one basis. Following these transactions, Paz directly holds 762,837 shares of Common Stock and 46,140 RSUs (derivative securities).
eXoZymes Inc., a pre-revenue synthetic biology company, reported a larger net loss of $5.25M for the six months ended June 30, 2026, compared with $4.22M a year earlier, driven mainly by an 85.7% increase in R&D spending to $2.56M. General and administrative costs declined 10.9% to $2.78M.
Cash and cash equivalents rose to $5.65M from $3.04M at year-end 2025, primarily from June 2026 equity offerings that generated $5.86M in net proceeds and added 732,260 shares and 366,130 warrants. Working capital reached $4.55M, but the company remains pre-revenue and used $3.16M in operating cash over six months.
Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing ongoing losses and funding needs despite near-term liquidity. A new warrant liability of $1.90M was recorded for investor warrants, and the company continues to rely on government research grants and future financings. Management also identified material weaknesses in internal control over financial reporting.
eXoZymes Inc. completed a $639,990 underwritten unit offering, selling 35,555 units at $18.00 each. Each unit consists of one share of common stock, priced at $8.99, and one warrant to buy one share.
The company plans to use net proceeds for its N‑trans‑caffeoyltyramine (NCT) technology, additional products, research and development, and general corporate purposes. Investor warrants become exercisable on June 5, 2027 at $11.24 per share, can be redeemed by the company once trading and registration conditions are met, and include a potential Warrant Reset that can lower the exercise price to $0.001 if specific holding and pricing conditions are satisfied.
eXoZymes Inc. is offering 35,555 units, each unit consisting of two shares of common stock and one warrant, representing 71,110 shares and 35,555 warrants sold together at $18.00 per unit. The warrants are exercisable from June 5, 2027 through June 5, 2031 at an initial exercise price of $11.24, subject to a one-time reset to $0.001 if the company issues later shares at a lower price prior to June 5, 2027 and certain holding conditions are met.
The placement agent is MDB Capital, an affiliate and substantial shareholder (holding 4,136,426 shares; 43.9% pre-offering). Net proceeds to the company are estimated at approximately $565,206. Shares outstanding prior to the offering are 9,210,249; as adjusted shares outstanding after this offering will be 9,281,359. The company discloses substantial going-concern risk and expects additional capital needs.
eXoZymes Inc. announced it has received a Notice of Award from the National Institute of General Medical Sciences of the NIH for a Phase IIB SBIR grant totaling $2,028,518. The two-year, non-dilutive grant is expected to begin on July 1, 2026 and supports development of rare cannabinoids and engineered cannabinoid analogs for pharmaceutical evaluation.
This award adds a second biosolution to eXoZymes’ pipeline after its NCT program and brings the company’s total non-dilutive funding to $19.7 million. Management highlights the grant as validation of its AI-enhanced, cell-free enzyme platform for scalable production of high-purity cannabinoids and new-to-nature molecules targeting future licensing and partnership opportunities.
eXoZymes Inc. completed an underwritten public offering of common stock and warrants, raising approximately $5.95 million in gross proceeds, including a partial exercise of the underwriters’ over-allotment option.
The company sold units combining common shares and warrants, with MDB Capital as sole book‑running manager, and plans to use the net proceeds to advance its N‑trans‑caffeoyltyramine (NCT) program, additional product opportunities, research and development, and general corporate and working capital needs.
eXoZymes Inc. is raising approximately $5.33 million through an underwritten public unit offering of common stock and warrants priced at $18.00 per unit. Each unit includes two shares and one warrant, with the offering made off an effective Form S-3 shelf registration.
The underwriter has a 45-day option to buy additional units, which could lift gross proceeds to $6.13 million before fees. Warrants become exercisable one year after the offering at $11.24 per share, can be redeemed once the stock trades at or above $17.98 for twenty out of thirty trading days, and include a reset feature that can cut the exercise price to $0.001 if eXoZymes sells stock or convertible securities below $8.99 within twelve months, subject to strict holding-period conditions for original investors.
Net proceeds, after underwriting commissions of about $0.37 million and estimated offering expenses of $0.25 million, are earmarked to advance the company’s N-trans-caffeoyltyramine (NCT) programs, other research and development, and general corporate and working capital needs.
eXoZymes Inc. is offering 592,270 shares of common stock and 296,135 warrants as units (two shares plus one warrant) pursuant to a prospectus supplement. Units are priced at $18.00 per unit; the offering includes a 45-day 15% over-allotment option. Each Warrant is exercisable beginning one year after the offering at $11.24 and expires five years after issuance, with a one-time exercise-price reset provision to $0.001 under specified conditions and a redemption feature at $0.01 per Warrant when the share price meets the stated trigger. Net proceeds are estimated at approximately $4,704,300 (or $5,447,891 if the over-allotment is exercised) to be used for developing the Company’s NCT program, next-in-line products, R&D, working capital and capital expenditures.